scholarly journals Classroom Experiments on Technology Licensing: Royalty Stacking, Cross-Licensing and Patent Pools

2021 ◽  
Author(s):  
Atle Haugen ◽  
Steffen Juranek
Author(s):  
Susobhan Goswami

In the last decade or so, strategic alliances and partnerships among pharmaceutical and biotech companies have doubled to around 700 per year per sector, although most of this increase came in the early years. Even though all big pharma companies have a good selling and marketing capacity, many alliances are created to optimise the commercialization of products, for example, through targeting different segments, marketing with synergistic products or in particular territories where a firm is stronger than the originator. Various forms of strategic partnerships such as collaborative research, contract research, co-production agreements, co-marketing arrangements, cross-distribution arrangements, and technology licensing are being utilized for capacity additions, brand acquisitions, marketing channel integration, and R&D integration, depending upon the focus of a firm. Indian firms are forking out contracts, alliances, and are entering into outsourcing deals where they lack strategic capabilities. But a few firms are looking to build long term capabilities and entering into Research and Development alliances.


2020 ◽  
Vol 10 (3) ◽  
pp. 233
Author(s):  
Erika Sofía Olaya Escobar ◽  
Maria Belén Arias Valle ◽  
Anna Akhmedova

2021 ◽  
pp. 2150041
Author(s):  
YUANZHU LU ◽  
FULAN WU

This paper extends Banerjee and Poddar [Banerjee, S and S Poddar (2019). ‘To sell or not to sell’: Licensing versus selling by an outside innovator. Economic Modelling, 76, 293–304] by lifting the cap on per unit royalty rates in the cases of royalty licensing and two-part tariff licensing. We reconsider the optimal technology licensing contract by an outside innovator facing two heterogeneous licensees in a standard Hotelling framework. Our findings show that the optimal licensing policy could be fixed fee to the efficient firm, or two-part tariff to both firms (pure royalty to both firms), or two-part tariff to the efficient firm, depending upon the cost differentials between the firms and the size of innovation.


Sign in / Sign up

Export Citation Format

Share Document